Chronic hyperglycemia contributes to diabetic neuropathy, retinopathy, and nephropathy, impacting multiple organ systems and significantly reducing quality of life. Neuropathy manifests as sensory loss, pain, or autonomic dysfunction, requiring early intervention with neuroprotective agents. Retinopathy progresses from mild non-proliferative changes to vision-threatening proliferative stages, necessitating routine ophthalmic evaluations. Nephropathy, a leading cause of end-stage renal disease, is managed through glycemic control, blood pressure regulation, and renoprotective medications like SGLT2 inhibitors. Emerging therapies, including regenerative medicine and targeted molecular interventions, offer hope for slowing or reversing disease progression. Early diagnosis and multidisciplinary management remain key in preventing irreversible damage.
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Diabetes reduction (pre diabetes and type 2) with integrative medicine
F Buck Willis, Christian College of Medicine, Belize
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : AI receptor binding studies reveal GPR146 conformational states across diabetic phenotypes: Analysis of C peptide and insulin interactions in cholesterol metabolism cortisol regulation and the vitamin D renin angiotensin axis
David Petch, utR Biotech, Canada
Title : Comparative outcomes of antihypertensive therapy in black vs non hispanic white patients with hypertension and cardiovascular disease
Anil Harrison, Midwestern University, United States